|
1
|
Damy T, Maurer MS, Heitner SB, Drachman BM, Whela CJ, Judge DP, Guthrie S, Tai LJ, Hughes S, Monia BP, Ackermann E, Benson MD. P685Hereditary transthyretin amyloidosis is associated with significant disease burden: analysis of the baseline characteristics of patients from the phase 3 study NEURO-TTR. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Damy
- National Referral Center for Cardiac Amyloidosis, Cardiology, Creteil, France
| | - M S Maurer
- Columbia University Medical Center, New York, United States of America
| | - S B Heitner
- Oregon Health & Science University, Portland, United States of America
| | - B M Drachman
- University of Pennsylvania, Philadelphia, United States of America
| | - C J Whela
- University College London, National Amyloidosis Center, London, United Kingdom
| | - D P Judge
- Medical University of South Carolina, Charleston, United States of America
| | - S Guthrie
- Independant Consultant, San Francisco, United States of America
| | - L J Tai
- Ionis Pharmaceuticals, Carlsbad, United States of America
| | - S Hughes
- Ionis Pharmaceuticals, Carlsbad, United States of America
| | - B P Monia
- Ionis Pharmaceuticals, Carlsbad, United States of America
| | - E Ackermann
- Ionis Pharmaceuticals, Carlsbad, United States of America
| | - M D Benson
- Ionis Pharmaceuticals, Carlsbad, United States of America
| |
Collapse
|